Literature DB >> 30149785

Human brucellosis: Experience from a tertiary care hospital in southern India.

Sudipta Patra1, Vandana Ke2, Chaitanya Tellapragada3, Chiranjay Mukhopadhyay4.   

Abstract

The aim of our study was to examine and compare the clinical presentations, complications, laboratory findings, treatment and outcome of patients with acute, subacute and chronic forms of brucellosis in a tertiary care setting. This hospital-based observational study was undertaken between April 2015 and March 2017. Patients diagnosed with brucellosis, either by blood culture and/or serology, were recruited. A total of 94 cases of brucellosis of acute, subacute and chronic forms were observed in 78.7%, 15.9% and 5.3%, respectively. Blood culture grew Brucella spp. in 70.2% cases. Serological tests showed positivity in 96.8% of the patients. Using multivariate logistic regression analysis, fever and upper back pain were significant predictors for both acute and chronic forms of the disease, respectively. There is a need to increase awareness and understand the local sero-epidemiological pattern of brucellosis as it is still little known.

Entities:  

Keywords:  Brucellosis; Diagnosis; bacterial infection; epidemiology

Mesh:

Substances:

Year:  2018        PMID: 30149785     DOI: 10.1177/0049475518788467

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  2 in total

1.  Epidemiological features of human brucellosis in Tongliao City, Inner Mongolia province, China: a cross-sectional study over an 11-year period (2007-2017).

Authors:  Di Li; Lifei Li; Jingbo Zhai; Lingzhan Wang; Bin Zhang
Journal:  BMJ Open       Date:  2020-01-02       Impact factor: 2.692

2.  Epidemiological, Clinical and Laboratory Characteristics of Patients with Brucella Infection in Anhui Province, China.

Authors:  Cuixiao Shi; Lianzi Wang; Dongmei Lv; Gang Wang; Hylemariam Mihiretie Mengist; Tengchuan Jin; Bo Wang; Ying Huang; Yajuan Li; Yuanhong Xu
Journal:  Infect Drug Resist       Date:  2021-07-16       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.